세포주 개발 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

Cell Line Development Market is projected to record a 10.3% CAGR from 2024 to 2032, driven by a surge in product launches and technological innovations.

Biotech firms and researchers are harnessing cutting-edge techniques like CRISPR gene editing, automation, and high-throughput screening, aiming to craft cell lines that are both efficient and reliable. These technological strides are not only accelerating the development of cell lines but also bolstering their precision for diverse applications, spanning drug discovery, therapeutic production, and biomedical research. For example, in June 2023, KBI Biopharma, under the umbrella of JSR Life Sciences, unveiled the KBI PURE platform. This innovative microbial cell line development platform is poised to enhance microbial expression efficiencies, especially for biopharmaceutical production.

The overall market is segregated into products and services, source, cell line, application, end-use, and region.

In terms of source, the mammalian segment in the cell line development market will experience significant growth by 2032 driven by an escalating demand in biopharmaceutical production. Researchers are counting on mammalian cells while employing genetic engineering techniques to boost productivity and stability, thereby producing vital therapeutic proteins and antibodies. Moreover, with these advancements, mammalian-derived cell lines are generating high-quality therapeutics, catering to the rising appetite for sophisticated medical treatments.

By application, the cell line development industry value from the drug discovery segment is projected to rise from 2024 to 2032. This can be attributed to the escalating need for precise and efficient therapeutic testing models. By crafting specialized cell lines that emulate human physiology, scientists are gaining deeper insights into drug interactions and effects. This ongoing refinement in cell line development is paving the way for more accurate drug testing, ultimately expediting the discovery of new medications.

Regionally, the Asia Pacific cell line development market size is projected to exhibit robust growth between 2024 and 2032, fueled by the growing focus on regenerative medicine. Researchers and biotech companies are leveraging advanced cell line technologies to develop therapies for repairing or replacing damaged tissues and organs. The ongoing evolution in cell line development will also support the advancement of regenerative medicine to offer new hope for treating a wide range of medical conditions across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing vaccine production worldwide
    • 3.2.1.2 Increasing prevalence of cancer across globe
    • 3.2.1.3 Technological innovation in cell line development
    • 3.2.1.4 Growing biotechnology industry
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Complex regulatory landscape
    • 3.2.2.2 Issues related to stem cell research
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Products and Services, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Reagents and media
• 5.3 Equipment
  • 5.3.1 Incubator
  • 5.3.2 Centrifuges
  • 5.3.3 Bioreactors
  • 5.3.4 Storage equipment
  • 5.3.5 Microscopes
  • 5.3.6 Electroporators
  • 5.3.7 Fluorescence-activated cell sorting
  • 5.3.8 Other equipment
• 5.4 Accessories and consumables
• 5.5 Services

Chapter 6 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Mammalian
• 6.3 Non-mammalian
  • 6.3.1 Insects
  • 6.3.2 Amphibians

Chapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Recombinant
• 7.3 Hybridomas
• 7.4 Continuous cell lines
• 7.5 Primary cell lines

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Bioproduction
• 8.3 Drug discovery
• 8.4 Toxicity testing
• 8.5 Tissue engineering
• 8.6 Research applications

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology companies
• 9.3 Academic and research institutes
• 9.4 Contract research organizations (CROs)

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 The Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Advanced Instruments, LLC
• 11.2 Aragen Life Sciences Ltd.
• 11.3 ASIMOV
• 11.4 Cytiva (Danaher Corporation)
• 11.5 Eurofins Scientific
• 11.6 Fyonibio
• 11.7 GenScript Biotech
• 11.8 Lonza Group AG
• 11.9 Novartis AG
• 11.10 ProBioGen
• 11.11 PromoCell
• 11.12 Sartorius AG
• 11.13 Sigma Aldrich (Merck KGaA)
• 11.14 Thermo Fisher Scientific Inc.
• 11.15 WuXi AppTec